HighTide Therapeutics Inc (2511.HK)
2511.HK Stock Price Chart
Explore HighTide Therapeutics Inc interactive price chart. Choose custom timeframes to analyze 2511.HK price movements and trends.
2511.HK Company Profile
Discover essential business fundamentals and corporate details for HighTide Therapeutics Inc (2511.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Dec 2023
Employees
70.00
Website
https://www.hightidetx.comCEO
Liping Liu
Description
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.
2511.HK Financial Timeline
Browse a chronological timeline of HighTide Therapeutics Inc corporate events including earnings releases, dividend announcements, and stock splits.
2511.HK Stock Performance
Access detailed 2511.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.